BARUFFINI, Enrico
 Distribuzione geografica
Continente #
NA - Nord America 1951
EU - Europa 1583
AS - Asia 728
Continente sconosciuto - Info sul continente non disponibili 10
AF - Africa 1
SA - Sud America 1
Totale 4274
Nazione #
US - Stati Uniti d'America 1927
CN - Cina 609
IT - Italia 592
SE - Svezia 345
FI - Finlandia 285
UA - Ucraina 140
DE - Germania 138
TR - Turchia 93
CA - Canada 23
GB - Regno Unito 23
BE - Belgio 21
FR - Francia 14
VN - Vietnam 10
EU - Europa 9
CZ - Repubblica Ceca 6
IR - Iran 6
NL - Olanda 6
IN - India 5
HK - Hong Kong 4
RO - Romania 4
IE - Irlanda 3
PL - Polonia 3
A2 - ???statistics.table.value.countryCode.A2??? 1
BR - Brasile 1
CH - Svizzera 1
DK - Danimarca 1
DM - Dominica 1
EG - Egitto 1
ES - Italia 1
KR - Corea 1
Totale 4274
Città #
Chandler 430
Ann Arbor 213
Parma 205
Dearborn 182
Jacksonville 170
Beijing 154
Nanjing 121
Princeton 100
Izmir 90
Wilmington 80
San Mateo 47
Shenyang 36
Jinan 34
Hefei 31
Woodbridge 31
Helsinki 30
Des Moines 28
Falls Church 28
Nanchang 27
Dosolo 26
Hebei 25
Kunming 23
Tianjin 23
Boardman 22
Toronto 21
Brussels 20
Guangzhou 19
Redmond 19
Changsha 16
Houston 15
Haikou 13
Dong Ket 10
Seattle 10
Zhengzhou 10
Fairfield 9
Fremont 9
Jiaxing 9
Redwood City 9
Ashburn 8
Sorbolo 8
Gravina di Catania 7
Hangzhou 7
Scafati 7
Taizhou 7
Ardea 6
Bologna 6
Fuzhou 6
Milan 6
Modena 6
Pavia 6
Rockville 6
Bremen 5
Ningbo 5
Ravenna 5
Cambridge 4
Castelnuovo Rangone 4
Norwalk 4
Pittsburgh 4
Reggio Nell'emilia 4
Vicenza 4
Wuhan 4
Xian 4
Zanjan 4
Auburn Hills 3
Borås 3
Brno 3
Düsseldorf 3
Kocaeli 3
Rome 3
Shanghai 3
Bangalore 2
Borgonovo Val Tidone 2
Brescia 2
Carpi 2
Castellarano 2
Chengdu 2
Chongqing 2
Cordovado 2
Dalmine 2
Fiorano Modenese 2
Grafing 2
Huzhou 2
Las Vegas 2
London 2
Los Angeles 2
New Delhi 2
Newcastle Upon Tyne 2
Ottawa 2
Philadelphia 2
San Remo 2
Solignano 2
Taiyuan 2
Timisoara 2
Trezzano Sul Naviglio 2
Wenzhou 2
Alghero 1
Andover 1
Baldwin City 1
Cairo 1
Campogalliano 1
Totale 2558
Nome #
Saccharomyces cerevisiae as a model to study the role of mutations in SDHA gene associated to hereditary optic neuropathies 261
DNA polymerase [gamma] and disease: what we have learned from yeast 80
Genetic and chemical rescue of the Saccharomyces cerevisiae phenotype induced by mitochondrial DNA polymerase mutations associated with progressive externalophthalmoplegia in humans 77
Biallelic Mutations in DNM1L are Associated with a Slowly Progressive Infantile Encephalopathy 75
COMPOUNDS FOR THE TREATMENT OF MITOCHONDRIAL DISEASES 75
Construction and validation of a yeast model system for studying in vivo the susceptibility to stavudine of DNA polymerase gamma allelic variants 72
Validation of a MGM1/OPA1 chimeric gene for functional analysis in yeast of mutations associated with dominant optic atrophy 71
YEAST MODEL FOR NOVEL AARS2 MUTATIONS ASSOCIATED WITH PROGRESSIVE LEUKOENCEPHALOPATHY AND CEREBELLAR ATAXIA 69
Defective PITRM1 mitochondrial peptidase is associated with Aβ amyloidotic neurodegeneration 69
Clinical-genetic features and peculiar muscle histopathology in infantile DNM1L-related mitochondrial epileptic encephalopathy 69
A chemical genomic approach to characterize the antiproliferative activity of metal based drugsdriven by phenotypic screening in yeast as a model organism 68
Yeast equivalents of disease associated human POLG mutations show deleterious cooperative effects in vivo 67
Validation of a MGM1/OPA1 chimeric gene for functional analysis in yeast of mutations associated with dominant optic atrophy 67
COMPOUNDS FOR THE TREATMENT OF MITOCHONDRIAL DISEASES 67
Dominance of yeast aac2R96H and aac2R252G mutations, equivalent to pathological mutations in ant1, is due to gain of function 66
Polymorphisms in DNA polymerase γ affect the mtDNA stability and the NRTI-induced mitochondrial toxicity in Saccharomyces cerevisiae 66
Biallelic Mutations of Methionyl-tRNA Synthetase Cause a Specific Type of Pulmonary Alveolar Proteinosis Prevalent on Réunion Island 65
S. cerevisiae carrying a MGM1/OPA1 chimeric gene: a model for the study of dominant optic atrophy and for drug discovery 64
Mechanistic insights on the mode of action of an antiproliferative thiosemicarbazone-nickel complex revealed by an integrated chemogenomic profiling study 63
Combined use of Saccharomyces cerevisiae, Caenorhabditis elegans and patient fibroblasts leads to the identification of Clofilium tosylate as a potential therapeutic chemical against POLG-related diseases 62
Deciphering OPA1 mutations pathogenicity by combined analysis of human, mouse and yeast cell models 62
A single nucleotide polymorphism in the DNA polymerase gamma gene of Saccharomyces cerevisiae laboratory strains is responsible for increased mitochondrial DNA mutability 61
Pathological alleles of MPV17 modeled in the yeast Saccharomyces cerevisiae orthologous gene SYM1 reveal their inability to take part in a high molecular weight complex 61
Yeast as a model of mitochondrial dysfunctions: neurodegenerative diseases and cancer. 60
Drug repositioning as a therapeutic strategy for neurodegenerations associated with OPA1 mutations 58
COMPOUNDS FOR THE TREATMENT OF MITOCHONDRIAL DISEASES 57
VARS2 and TARS2 Mutations in Patients with Mitochondrial Encephalomyopathies 56
Saccharomyces cerevisiae, a model system to study the effect of mtDNA polymerase mutations associated with PEO in humans. 53
A chemical genomic approach to characterize the antiproliferative activity of metal-based drugs driven by phenotipic screening in yeast as a model organism 52
Mitochondrial PITRM1 peptidase loss-of-function in childhood cerebellar atrophy 52
Construction and characterization of centromeric, episomal and GFP-containing vectors for Saccharomyces cerevisiae prototrophic strains 51
OPA1 Isoforms in the Hierarchical Organization of Mitochondrial Functions 51
Amino and carboxy-terminal extensions of yeast mitochondrial DNA polymerase assemble both the polymerization and exonuclease active sites 51
Construction and validation of a yeast model system for studying in vivo the susceptibility to stavudine of Polg allelic variants 49
The power of yeast in modeling human mutations leading to mitochondrial disease:the case of ANT1, YARS2, DNM1L and LYRM7. 49
Mitochondrial Aminoacyl-tRNA Synthetase: The Power Of Yeast In Modeling Human Pathological Mutations 49
Yeast, worm, patient’s fibroblasts and zebrafish as models for drug repositioning of molecules targeting POLG-related diseases 49
Overexpression of DNA Polymerase Zeta Reduces the Mitochondrial Mutability Caused by Pathological Mutations in DNA Polymerase Gamma in Yeast 48
Predicting the contribution of novel POLG mutations to human disease through analysis in yeast model 48
Hsp12p and PAU genes are involved in ecological interactions between natural yeast strains 48
Galactose transport in Kluyveromyces lactis: a genomic approach 48
The identification of beneficial molecules for mitochondrial diseases: Saccharomyces cerevisiae as powerful model 47
Glutamate dehydrogenase isoenzyme 3 (GDH3) of Arabidopsis thaliana is less thermostable than GDH1 and GDH2 isoenzymes 46
Yeast as a model for drug repositioning: analysis of molecules acting as potential therapeutics for POLG-related diseases 46
Mitmed: a multicenter consortium for the identification and characterization of nuclear genes responsisble for human mitochondrial disorders 46
Modeling of pathogenic variants of mitochondrial DNA polymerase: insight into the replication defects and implication for human disease 46
Galactose transport in Kluyveromyces lactis: major role of the glucose permease Hgt1 45
Yeast as a model for drug discovery: identification of a molecule acting as potential therapeutics for POLG-related diseases 45
Overexpression of DNA polymerase zeta reduces the mitochondrial mutability caused by pathological mutations in DNA polymerase gamma in yeast. 45
Saccharomyces cerevisiae as a model for the identification of beneficial molecules for mitochondrial diseases. 45
A variable neurodegenerative phenotype with polymerase gamma mutation 44
Construction and validation of a yeast model system for studying in vivo the susceptibility to nucleoside analogues of DNA polymerase gamma allelic variants. 44
Saccharomyces cerevisiae as a system to discover beneficial molecules for mitochondrial diseases 44
Glutamate dehydrogenase isoenzyme 3 (GDH3) of Arabidopsis thaliana is less thermostable than GDH1 and GDH2 isoenzymes 43
Mitochondrial DNA defects in Saccharomyces cerevisiae caused by functional interactions between DNA polymerase gamma mutations associated with disease in human 43
Overexpression of DNA polymerase zeta and Rev1 reduces the mitochondrial mutability caused by pathological mutations in DNA polymerase gamma in yeast. 42
MTO1 mutations are associated with hypertrophic cardiomyopathy and lactic acidosis and cause respiratory chain deficiency in humans and yeast 42
Mitochondrial disorders caused by mutations impairing miotchondrial dynamics 42
Galactose transport in Kluyveromyces lactis 41
Construction of a yeast model system for studying in vivo susceptibility to stavudine of Polg allelic variants 41
Mutations of the mitochondrial-tRNA modifier MTO1 cause hypertrophic cardiomyopathy and lactic acidosis. 41
Defective i6A37 Modification of Mitochondrial and Cytosolic tRNAs Results from Pathogenic Mutations in TRIT1 and Its Substrate tRNA 41
Investigation of mupirocin susceptibility in bifidobacteria: physiological and genetic insights. 41
MITMED: A MULTICENTER CONSORTIUM FOR THE IDENTIFICATION AND CHARACTERIZATION OF NUCLEAR GENES RESPONSIBLE FOR HUMAN MITOCHONDRIAL DISORDERS 41
How to easily detect plant NADH-glutamate dehydrogenase (GDH) activity? A simple and reliable in planta procedure suitable for tissues, extracts and heterologous microbial systems 41
Clinical and molecular features of mitochondrial DNA depletion syndromes. 40
Yeast as a model for drug discovery: Identification of a molecule acting as potential therapeutics for POLG-related diseases 40
Rescue by Pol zeta overexpression of mitochondrial DNA instability due to mutations in Pol gamma in S. cerevisiae 39
A combination of two novel VARS2 variants causes a mitochondrial disorder associated with failure to thrive and pulmonary hypertension 39
The Power of Yeast in Modelling Human Nuclear Mutations Associated with Mitochondrial Diseases 39
In-frame deletion in canine PITRM1 is associated with a severe early-onset epilepsy, mitochondrial dysfunction and neurodegeneration 39
Studio nel sistema modello Saccharomyces cerevisiae di mutazioni patologiche nel gene POLG codificante la DNA polimerasi mitocondriale 38
Galactose transport in Kluyveromyces lactis: a genomic approach 38
Genetic rescue by enzymes involved in mitochondrial DNA repair of Saccharomyces cerevisiae phenotypes induced by mitochondrial DNA polymerase mutations 38
Galactose transporters discriminate steric anomers at the cell surface in yeast 37
Yeast model for drug discovery: Identification of molecules acting as potential therapeutics for POLG-related diseases 37
COMMON POLG GENETIC VARIANTS INCREASE THERISK OF SODIUM VALPROATE INDUCED LIVER INJURYAND FAILURE 37
The power of yeast in modeling human mutations: mitochondrial aminoacyl tRNA synthetases and mitochondrial tRNA modifiers 36
Efficient clofilium tosylate-mediated rescue of POLG-related disease phenotypes in zebrafish 36
Yeast equivalents of disease-associated human Polg mutations show deleterious cooperative effects in vivo 35
Yeast equivalents of disease-associated human POLG mutations show deleterious cooperative effects. 33
In vivo analysis of mtDNA replication defects in yeast 33
Hsp12p and PAU genes are involved in ecological interactions between natural yeast strains 33
POLG determines the risk of sodium valproate induced liver toxicity 31
A yeast-based repurposing approach revealed modulation of dNTP pool as a therapeutic target to treat mitochondrial DNA depletion syndromes 30
Glutamate dehydrogenase isoenzyme 3 (GDH3) of Arabidopsis thaliana is less thermostable than GDH1 and GDH2 isoenzymes 29
The power of yeast in modeling human mutations leading to mitochondrial disease 29
Mutation in the MICOS subunit gene APOO (MIC26) associated with an X-linked recessive mitochondrial myopathy, lactic acidosis, cognitive impairment and autistic features 28
Novel (ovario) leukodystrophy related to AARS2 mutations 28
Pre-clinical identification of drugs targeting polg disorders by using a zebrafish/yeast trans-species approach (ZIPPY) 25
Unprocessed RNA intermediates interfere with mitochondrial translation and cause respiratory chain deficiency 23
ELAC2 Mutations Cause a Mitochondrial RNA Processing Defect Associated with Hypertrophic Cardiomyopathy 23
Mutations of the mitochondrial-tRNA modifier MTO1 cause hypertrophic cardiomyopathy and lactic acidosis 23
MTO1 MUTATIONS CAUSE RESPIRATORY CHAIN DEFICIENCY IN HUMANS AND YEAST 21
Saccharomyces cerevisiae as a tool for studying mutations in nuclear genes involved in diseases caused by mitochondrial DNA instability 21
Bi-allelic KARS1 pathogenic variants affecting functions of cytosolic and mitochondrial isoforms are associated with a progressive and multisystem disease 20
Identification of drugs for the treatment of POLG-related diseases by means of a high throughput drug repurposing approach performed in Saccharomyces cerevisiae 19
Modeling in yeast of KARS pathogenic variants associated with a progressive and multi-systemic disease: impact on cytosolic and mitochondrial isoforms 19
A yeast-based repurposing approach for the treatment of mitochondrial DNA depletion syndromes led to the identification of molecules able to modulate the dNTP pool 18
Mitochondrial aminoacyl‐trna synthetase and disease: The yeast contribution for functional analysis of novel variants 17
Totale 4799
Categoria #
all - tutte 7715
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7715


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/2018241 0000 08 262 11312377
2018/2019236 311613 1119 117 19911512
2019/20201440 2052125715 80406 14133 124834044
2020/2021686 18434915 8143 6951 133479047
2021/2022534 23191026 2027 5055 294128206
2022/2023909 222222169148 1480 00 0000
Totale 4799